The National Academies Press

Currently Skimming:

APPENDIX A: PROMISE AND PROBLEMS . . . (FINAL AGENDA, LIST OF SPEAKERS AND PARTICIPANTS)
Pages 41-48

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.

From page 41... ... Appendix A Promise and Problems: Hib, Pneumococcal, and Meningococcal Vaccines in the Developing World September 12-13, 1994 Foundry Building, Room 2004 1055 Thomas Jefferson Street, NW Washington, D.C. Room 2004 FINAL AGENDA Day 1 8:30 Continental Breakfast 9:00 Welcome and Introduction Caroline Hall, Steering Committee Chair 9:10 Overview Floyd Denny, University of North Carolina 41 Read the entire page →
From page 42... ... 42 THE CHILDREN'S VACCINE INITIATIVE: CONTINUING ACTIVITIES 9:30 Determining Vaccine Need Moderator: Samuel Katz, Steering Committee Member Epidemiologic Data Gaps and Their Relevance to Vaccine Studies Mark Steinhoff, Johns Hopkins University � The Situation in Nigeria and the United Arab Emirates Catherine Oyejide, College of Medicine, Ibadan, Nigeria � Serotype Surprise: The Case of Haemophilus influenzoe in Egypt Mona Assad, VACSERA, Cairo, Egypt � The Global Burden of N menigitidis-Caused Meningitis Jay Wenger, Centers for Disease Control and Prevention 10:30 Break 10:45 Discussion 1 1:45 Lunch 12:45 Overcoming Technologic Barriers Moderator: Emil Gotschlich, Rockefeller University Pneumococcal Conjugate Vaccines: Status and Prospects John La Montagne, National Institutes of Health The Limits of Conjugate Technology Philip Russell, Children's Vaccine Initiative The Common-Antigen Approach to Vaccine Development David Briles, University of Alabama 1:30 Discussion 2:30 Break 2:45 A Meningococcal B Vaccine for Children Wendell Zollinger, Walter Reed Army Institute of Research Read the entire page →
From page 43... ... APPENDIX A One Approach to Constructing a Meningococcal A/B/C Vaccine Carl Frasch, Food and Drug Administration 3: 15 Discussion 4:00 Break 4:45 Adjourn 8:30 Continental Breakfast 43 Summary and Synthesis: Day 1 Moderators Day 2 9:00 Proving Vaccine Efficacy: The Challenge of Developing-Country Field Trials Moderator: George Siber, Massachusetts Department of Health Pneumonia Diagnostics: The Achilles Heel of ARI Epidemiology Claire Broome, Centers for Disease Control and Prevention The Case-Control Method and Other Alternative Design Strategies Helena Makela, National Public Health Institute, Helsinki, Finland Report of a Post-Licensure Hib Efficacy Trial in Chile Myron Levine, University of Maryland 9:45 Discussion 10:45 Break 11:00 The Public-/Private-Sector Interface Moderator: William Hubbard, Steering Committee Member � An Industry Perspective Peter Paradiso/Frank Malinoski, Lederle-Praxis Biologicals Read the entire page →
From page 44... ... 44 THE CHILDREN'S VACCINE INITIATIVE: CONTINUING ACTIVITIES � A Biotech Perspective Dale Spriggs, Virus Research Institute � A Government Perspective George Curlin, National Institutes of Health 1 1:45 Discussion 12:30 Lunch 1:15 Introducing an Effective Vaccine Moderator: Donald Shepard, Brandeis University The Cost-Effectiveness of ARI Vaccines Benjamin Schwartz, Centers for Disease Control and Prevention The Purchase and Cost of New EPI Vaccines Maria Costales, Ministry of Health, Philippines Financing the use of Conjugate Hib Vaccine in Brazil Otavio Oliva, SIREVA, Rio de Janiero, Brazil 2:00 Break 2:15 Facilitating Vaccine Production Capability George Siber, Massachusetts Department of Health The Importance of Infrastructure and National Commitment: Lessons from the Polio Experience Ciro de Quadros, Steering Committee Member 2:45 Discussion 3:45 Break 4:00 Summary and Synthesis: Day 2 Moderators 4:30 Closing Comments Caroline Hall, Steering Committee Chair Adjourn Read the entire page →
From page 45... ... John La Montagne, Ph.D., Director, Division of Microbiology and Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD Myron M Levine, M.D., D.T.P.H., Professor and Director, Center for Vaccine Development, University of Maryland, Baltimore, MD Helena Makela, M.D., Ph.D., Director, Division of Infectious Diseases, National Public Health Institute, Helsinki, Finland Frank J Read the entire page →
From page 46... ... Bale, Ph.D., Program Officer, Board on Science and Technology for International Development, Washington, DC Kenneth Bart, M.D., Associate Director for Medical and Scientific Affairs, Office of International Health, U.S. Public Health Service, Rockville, MD Alfred Bartlett, M.D., M.P.H., Acting Chief, Child Survival Division, Office of Health and Nutrition, Agency for International Development, Washington, DC Ruth Brenner, M.D., Senior Staff Fellow, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD Robert Clay, M.P.H., Acting Deputy Director, Office of Health and Nutrition, Agency for International Development, Washington, DC John Clemens, M.D., Chief, Epidemiology Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD Jose Luis Di Fabio, Advisor on Vaccines, Pan American Health Organization, Washington, DC Gerald W Read the entire page →
From page 47... ... Klein, Ph.D., Bacterial Respiratory Disease Program Officer, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD Kaimi Lin, M.D., Medical Research Officer, National Institute of Child Health and Human Development, National Institutes of Health, Rockville, MD Sharon Mates, Ph.D., President, North American Vaccine Inc., Beltsville, MD Paul M Mendelman, Merck Research Laboratories, West Point, PA Molly Mort, Ph.D., AAAS Fellow, Office of Health and Nutrition, Agency for International Development, Washington, DC Trudy Murphy, M.D., Associate Professor of Pediatrics, University of Texas, Southwestern Medical Center/Dallas, Dallas, TX David Got, M.P.H., Director, Office of Health and Nutrition, Agency for International Development, Washington, DC Jan T Read the entire page →
From page 48... ... 48 THE CHILDREN'S VACCINE INITLi4TIVE: CONTINUING ACTIVITIES Ronnie Waldman, M.D., M.P.H., Deputy Director/Technical, BASICS, Agency for International Development, Washington, DC Joel I Ward, M.D., Chief, Pediatric Infectious Diseases, Harbor-University of California/LA, Torrance, CA Roy Widdus, Ph.D., Office of the Assistant Secretary for Health, National Vaccine Program Office, Rockville, MD James Young, Ph.D., Vice President, Research and Development, MedImmune, Gaithersburg, MD Paul Zeitz, D.O., M.P.H., Child Survival Fellow, Agency for International Development, Office of Health and Nutrition, Washington, DC Beatrice Zurita, London School of Hygiene and Tropical Medicine, University of London, London, England Staff Greg Pearson, Project Director Dee Sutton, Administrative Assistant Read the entire page →

From page 41...

... Appendix A Promise and Problems: Hib, Pneumococcal, and Meningococcal Vaccines in the Developing World September 12-13, 1994 Foundry Building, Room 2004 1055 Thomas Jefferson Street, NW Washington, D.C. Room 2004 FINAL AGENDA Day 1 8:30 Continental Breakfast 9:00 Welcome and Introduction Caroline Hall, Steering Committee Chair 9:10 Overview Floyd Denny, University of North Carolina 41

Read the entire page →

From page 42...

... 42 THE CHILDREN'S VACCINE INITIATIVE: CONTINUING ACTIVITIES 9:30 Determining Vaccine Need Moderator: Samuel Katz, Steering Committee Member Epidemiologic Data Gaps and Their Relevance to Vaccine Studies Mark Steinhoff, Johns Hopkins University � The Situation in Nigeria and the United Arab Emirates Catherine Oyejide, College of Medicine, Ibadan, Nigeria � Serotype Surprise: The Case of Haemophilus influenzoe in Egypt Mona Assad, VACSERA, Cairo, Egypt � The Global Burden of N menigitidis-Caused Meningitis Jay Wenger, Centers for Disease Control and Prevention 10:30 Break 10:45 Discussion 1 1:45 Lunch 12:45 Overcoming Technologic Barriers Moderator: Emil Gotschlich, Rockefeller University Pneumococcal Conjugate Vaccines: Status and Prospects John La Montagne, National Institutes of Health The Limits of Conjugate Technology Philip Russell, Children's Vaccine Initiative The Common-Antigen Approach to Vaccine Development David Briles, University of Alabama 1:30 Discussion 2:30 Break 2:45 A Meningococcal B Vaccine for Children Wendell Zollinger, Walter Reed Army Institute of Research

Read the entire page →

From page 43...

... APPENDIX A One Approach to Constructing a Meningococcal A/B/C Vaccine Carl Frasch, Food and Drug Administration 3: 15 Discussion 4:00 Break 4:45 Adjourn 8:30 Continental Breakfast 43 Summary and Synthesis: Day 1 Moderators Day 2 9:00 Proving Vaccine Efficacy: The Challenge of Developing-Country Field Trials Moderator: George Siber, Massachusetts Department of Health Pneumonia Diagnostics: The Achilles Heel of ARI Epidemiology Claire Broome, Centers for Disease Control and Prevention The Case-Control Method and Other Alternative Design Strategies Helena Makela, National Public Health Institute, Helsinki, Finland Report of a Post-Licensure Hib Efficacy Trial in Chile Myron Levine, University of Maryland 9:45 Discussion 10:45 Break 11:00 The Public-/Private-Sector Interface Moderator: William Hubbard, Steering Committee Member � An Industry Perspective Peter Paradiso/Frank Malinoski, Lederle-Praxis Biologicals

Read the entire page →

From page 44...

... 44 THE CHILDREN'S VACCINE INITIATIVE: CONTINUING ACTIVITIES � A Biotech Perspective Dale Spriggs, Virus Research Institute � A Government Perspective George Curlin, National Institutes of Health 1 1:45 Discussion 12:30 Lunch 1:15 Introducing an Effective Vaccine Moderator: Donald Shepard, Brandeis University The Cost-Effectiveness of ARI Vaccines Benjamin Schwartz, Centers for Disease Control and Prevention The Purchase and Cost of New EPI Vaccines Maria Costales, Ministry of Health, Philippines Financing the use of Conjugate Hib Vaccine in Brazil Otavio Oliva, SIREVA, Rio de Janiero, Brazil 2:00 Break 2:15 Facilitating Vaccine Production Capability George Siber, Massachusetts Department of Health The Importance of Infrastructure and National Commitment: Lessons from the Polio Experience Ciro de Quadros, Steering Committee Member 2:45 Discussion 3:45 Break 4:00 Summary and Synthesis: Day 2 Moderators 4:30 Closing Comments Caroline Hall, Steering Committee Chair Adjourn

Read the entire page →

From page 45...

... John La Montagne, Ph.D., Director, Division of Microbiology and Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD Myron M Levine, M.D., D.T.P.H., Professor and Director, Center for Vaccine Development, University of Maryland, Baltimore, MD Helena Makela, M.D., Ph.D., Director, Division of Infectious Diseases, National Public Health Institute, Helsinki, Finland Frank J

Read the entire page →

From page 46...

... Bale, Ph.D., Program Officer, Board on Science and Technology for International Development, Washington, DC Kenneth Bart, M.D., Associate Director for Medical and Scientific Affairs, Office of International Health, U.S. Public Health Service, Rockville, MD Alfred Bartlett, M.D., M.P.H., Acting Chief, Child Survival Division, Office of Health and Nutrition, Agency for International Development, Washington, DC Ruth Brenner, M.D., Senior Staff Fellow, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD Robert Clay, M.P.H., Acting Deputy Director, Office of Health and Nutrition, Agency for International Development, Washington, DC John Clemens, M.D., Chief, Epidemiology Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD Jose Luis Di Fabio, Advisor on Vaccines, Pan American Health Organization, Washington, DC Gerald W

Read the entire page →

From page 47...

... Klein, Ph.D., Bacterial Respiratory Disease Program Officer, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD Kaimi Lin, M.D., Medical Research Officer, National Institute of Child Health and Human Development, National Institutes of Health, Rockville, MD Sharon Mates, Ph.D., President, North American Vaccine Inc., Beltsville, MD Paul M Mendelman, Merck Research Laboratories, West Point, PA Molly Mort, Ph.D., AAAS Fellow, Office of Health and Nutrition, Agency for International Development, Washington, DC Trudy Murphy, M.D., Associate Professor of Pediatrics, University of Texas, Southwestern Medical Center/Dallas, Dallas, TX David Got, M.P.H., Director, Office of Health and Nutrition, Agency for International Development, Washington, DC Jan T

Read the entire page →

From page 48...

... 48 THE CHILDREN'S VACCINE INITLi4TIVE: CONTINUING ACTIVITIES Ronnie Waldman, M.D., M.P.H., Deputy Director/Technical, BASICS, Agency for International Development, Washington, DC Joel I Ward, M.D., Chief, Pediatric Infectious Diseases, Harbor-University of California/LA, Torrance, CA Roy Widdus, Ph.D., Office of the Assistant Secretary for Health, National Vaccine Program Office, Rockville, MD James Young, Ph.D., Vice President, Research and Development, MedImmune, Gaithersburg, MD Paul Zeitz, D.O., M.P.H., Child Survival Fellow, Agency for International Development, Office of Health and Nutrition, Washington, DC Beatrice Zurita, London School of Hygiene and Tropical Medicine, University of London, London, England Staff Greg Pearson, Project Director Dee Sutton, Administrative Assistant

Read the entire page →

← Previous Chapter Skim

Next Chapter Skim →

This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.

APPENDIX A: PROMISE AND PROBLEMS . . . (FINAL AGENDA, LIST OF SPEAKERS AND PARTICIPANTS) Pages 41-48

APPENDIX A: PROMISE AND PROBLEMS . . . (FINAL AGENDA, LIST OF SPEAKERS AND PARTICIPANTS)
Pages 41-48